Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship

doi:10.4330/wjc.v15.i5.229

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3196)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

387

WORD

HTML

2009

Figures (1-5)

151

Tables (1-2)

171

Sum=2755

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

124

Download

317

Sum=441

May 26, 2023 (publication date) through May 11, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. May 26, 2023; 15(5): 229-243
Published online May 26, 2023. doi: 10.4330/wjc.v15.i5.229

Table 2 Impact of various antidiabetic agents on the burden of atrial fibrillation and coronary artery disease and their surrogate endpoints

Antidiabetic drug class	Impact on AF burden/ surrogate end points	Impact on CAD burden/ surrogate end points
Insulin[71]	Increased (↑)	Neutral or increased (-/↑)
Metformin[72]	Reduced (↓)	Reduced (↓)
Sulfonylureas[71]	Neutral (-/↑)	Increased (↑↑)
Thiazolidinediones[73]	Reduced or neutral (-/↓)	Increased (↑↑)
DPP-4 inhibitors[74]	Reduced (-/↓)	Reduced (↓)
GLP-1 receptor agonists[75]	Neutral or slightly increased (-/↑)	Reduced (↓↓)
SGLT-2 inhibitors[76]	Reduced (↓↓)	Reduced (↓↓↓)

AF: Atrial fibrillation; CAD: Coronary artery disease; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide 1; SGLT-2: Sodium-glucose cotransporter-2.

Citation: Batta A, Hatwal J, Batta A, Verma S, Sharma YP. Atrial fibrillation and coronary artery disease: An integrative review focusing on therapeutic implications of this relationship. World J Cardiol 2023; 15(5): 229-243
URL: https://www.wjgnet.com/1949-8462/full/v15/i5/229.htm
DOI: https://dx.doi.org/10.4330/wjc.v15.i5.229